A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer
This is an open-label, single-arm, Phase Ib/II investigator-initiated trial of RC48-ADC combined with JS001 to evaluate the safety and pharmacokinetics of subjects with locally advanced or metastatic urothelial cancer
Urothelial Carcinoma
DRUG: RC48-ADC and JS001
Adverse events, rate of adverse events, through study completion, an average of 1 year|maximal tolerated dose, dose-limiting toxity, through study completion, an average of 1 year
Peak Plasma Concentration(Cmax), Maximum observed plasma concentration, through study completion, an average of 1 year|Immunogenicity, Numbers of participants with anti-drug antibody positive, through study completion, an average of 1 year|objective response rate, evaluated by RECIST 1.1 every 8 weeks, From date of randomization until the date of first documented progression or date of death from any cause, whichever came firstï¼›assessed up to 60 months|the area under the curve (AUC), Area under the plasma concentration versus time curve, through study completion, an average of 1 year
This is an open-label, single-arm, Phase Ib/II investigator-initiated trial of RC48-ADC combined with JS001 to evaluate the safety and pharmacokinetics of subjects with locally advanced or metastatic urothelial cancer